FDA approves rivaroxaban for prevention of deep-vein thrombosis in surgery

Cardiovascular Journal of Africa

Volumn 22, Issue 4, 2011, Pages 218-

  Aalbers, J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; DABIGATRAN ETEXILATE; ENOXAPARIN; GLYCOPROTEIN P; HEPARIN; NADROPARIN; RIVAROXABAN;

BLEEDING; BLOOD CLOTTING DISORDER; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HIP ARTHROPLASTY; HUMAN; KIDNEY DYSFUNCTION; KNEE ARTHROPLASTY; LIVER DISEASE; PERIOPERATIVE PERIOD; POSTOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; RECOMMENDED DRUG DOSE; SHORT SURVEY; SOUTH AFRICA; SPINAL ANESTHESIA; THROMBOSIS PREVENTION; TREATMENT DURATION; TREATMENT RESPONSE; UNITED STATES;

ADMINISTRATION, ORAL; ANTICOAGULANTS; DRUG APPROVAL; FACTOR XA; HUMANS; MORPHOLINES; ORTHOPEDIC PROCEDURES; THIOPHENES; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VENOUS THROMBOSIS;

EID: 80052253638     PISSN: 19951892     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (3)

1. Stiles S. FDA approves oral anticoagulant rivaroxaban for DVT prevention at surgery. Heartwire, 1 July 2011.
2. http://www.accessdata.fda.gov/scripts/cder/ drugsatfda/index.cfm? fuseaction=Search.DrugDetails
3. Janssen Pharmaceuticals. FDA approves Xarelto to help prevent DVT in patients undergoing knee or hip replacement surgery. 2 July 2011.